1. Home
  2. CINF vs GMAB Comparison

CINF vs GMAB Comparison

Compare CINF & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cincinnati Financial Corporation

CINF

Cincinnati Financial Corporation

HOLD

Current Price

$156.52

Market Cap

25.4B

Sector

Finance

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$34.52

Market Cap

21.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CINF
GMAB
Founded
1950
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4B
21.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CINF
GMAB
Price
$156.52
$34.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$177.25
$40.00
AVG Volume (30 Days)
562.7K
2.0M
Earning Date
02-09-2026
02-11-2026
Dividend Yield
2.20%
N/A
EPS Growth
N/A
132.41
EPS
13.44
25.10
Revenue
$12,078,000,000.00
$3,845,670,022.00
Revenue This Year
$10.47
$24.85
Revenue Next Year
N/A
$16.51
P/E Ratio
$11.75
$1.33
Revenue Growth
N/A
29.57
52 Week Low
$123.02
$17.24
52 Week High
$169.86
$35.43

Technical Indicators

Market Signals
Indicator
CINF
GMAB
Relative Strength Index (RSI) 35.76 58.27
Support Level $155.14 $30.88
Resistance Level $159.64 $33.92
Average True Range (ATR) 2.83 0.97
MACD -0.69 0.00
Stochastic Oscillator 13.65 80.99

Price Performance

Historical Comparison
CINF
GMAB

About CINF Cincinnati Financial Corporation

Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The company operates in segments: Commercial lines insurance, Personal lines insurance, and Excess and surplus lines insurance, Life insurance, and Investments. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: